We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomer... Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often lead to end-stage kidney disease. Show more
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present eight posters in classical homocystinuria (HCU) at Society...
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the World Congress...
SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2024, the Compensation Committee of its Board of Directors granted...
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug...
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming investor conferences in...
Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe...
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy Canada NewsWire ST. GALLEN, Switzerland, Feb. 23, 2024 Committee for...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.46 | -7.41935483871 | 6.2 | 6.36 | 5.575 | 1016659 | 5.89678164 | CS |
| 4 | -2.12 | -26.9720101781 | 7.86 | 8.06 | 5.575 | 1203932 | 6.68140507 | CS |
| 12 | -3.45 | -37.5408052231 | 9.19 | 9.22 | 5.575 | 1164790 | 7.63555259 | CS |
| 26 | -1.31 | -18.5815602837 | 7.05 | 10.27 | 5.25 | 1414889 | 7.69436324 | CS |
| 52 | -15.52 | -73.0009407338 | 21.26 | 22.75 | 5.25 | 1439748 | 10.59015781 | CS |
| 156 | -19.27 | -77.0491803279 | 25.01 | 31.65 | 5.25 | 1078845 | 17.06184231 | CS |
| 260 | -19.41 | -77.1769383698 | 25.15 | 33.0899 | 5.25 | 1011977 | 17.71171023 | CS |
bikaver
6 months ago
bikaver
7 months ago
bikaver
7 months ago
Stockexpertpro
7 months ago
alchemytrader
3 years ago
cash4
3 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
